Citi initiated a 30-day catalyst watch for GoodRx Holdings while maintaining a Buy rating and a $4 price target.
The digital healthcare platform now captures approximately one-third of all transactions for the weight-loss drug Wegovy in its pill form.
This market penetration suggests potential for upward revisions to company earnings estimates. Analysts indicate that current forecasts may not fully reflect this specific revenue driver.